Tariffs & Trade Policy: What to Watch for, Cost Impacts, and Supply Chain Strategies
PharmTech
JULY 24, 2025
Meanwhile, the generic producers which I understand make up approximately 90% of US drug sales and have very thin profit margins to begin with. There's a limited ability to raise prices because of the reimbursement system and the insurance system and how drugs are paid for in our market. Policies and levels and insurance, right?
Let's personalize your content